Abstract:The E3 ubiquitin ligase adaptor speckle-type POZ protein (SPOP) is frequently dysregulated in prostate adenocarcinoma (PC), via either somatic mutations or mRNA downregulation, suggesting an important tumour suppressor function. To examine its physiologic role in the prostate epithelium in vivo, we generated mice with prostate-specific biallelic ablation of Spop. These mice exhibited increased prostate mass, prostate epithelial cell proliferation, and expression of c-MYC protein compared to littermate controls, and eventually developed prostatic intraepithelial neoplasia (PIN). We found that SPOPWT can physically interact with c-MYC protein and, upon exogenous expression in vitro, can promote c-MYC ubiquitination and degradation. This effect was attenuated in PC cells by introducing PC-associated SPOP mutants or upon knockdown of SPOP via short-hairpin-RNA, suggesting that SPOP inactivation directly increases c-MYC protein levels. Gene Set Enrichment Analysis revealed enrichment of Myc-induced genes in transcriptomic signatures associated with SPOPMT. Likewise, we observed strong inverse correlation between c-MYC activity and SPOP mRNA levels in two independent PC patient cohorts. The core SPOPMT;MYCHigh transcriptomic response, defined by the overlap between the SPOPMT and c-MYC transcriptomic programmes, was also associated with inferior clinical outcome in human PCs. Finally, the organoid-forming capacity of Spop-null murine prostate cells was more sensitive to c-MYC inhibition than that of Spop-WT cells, suggesting that c-MYC upregulation functionally contributes to the proliferative phenotype of Spop knock-out prostates. Taken together, our data highlight SPOP as an important regulator of luminal epithelial cell proliferation and c-MYC expression in prostate physiology, identify c-MYC as a novel bona fide SPOP substrate, and help explain the frequent inactivation of SPOP in human PC. We propose SPOPMT-induced stabilization of c-MYC protein as a novel mechanism that can increase total c-MYC levels in PC cells, in addition to amplification of c-MYC locus.

SPOP negatively regulates mTORC1 activity by ubiquitinating Sec13

TGF- signaling regulates <i>SPOP</i> expression and promotes prostate cancer cell stemness

SPOP Suppresses Tumorigenesis by Regulating Hedgehog/Gli2 Signaling Pathway in Gastric Cancer.

SPOP promotes SIRT2 degradation and suppresses non-small cell lung cancer cell growth.

SPOP promotes ubiquitination and degradation of LATS1 to enhance kidney cancer progression

Mtorc1 Accelerates Osteosarcoma Progression Via M6a-Dependent Stabilization of USP7 Mrna

SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression

SPOP Promotes Tumorigenesis by Acting As a Key Regulatory Hub in Kidney Cancer

SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase.

SPOP suppresses prostate cancer through regulation of CYCLIN E1 stability

SPOP Inhibits BRAF-dependent Tumorigenesis Through Promoting Non-Degradative Ubiquitination of BRAF

SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein

TGF-β signaling regulates SPOP expression and promotes prostate cancer cell stemness

SPOP Suppresses Pancreatic Cancer Progression by Promoting the Degradation of NANOG.

Tumor Suppressor SPOP Ubiquitinates and Degrades EglN2 to Compromise Growth of Prostate Cancer Cells.

SPOP point mutations regulate substrate preference and affect its function

SPOP in Cancer: Phenomena, Mechanisms and Its Role in Therapeutic Implications

Prostate Cancer-Associated Mutation in SPOP Impairs Its Ability to Target Cdc20 for Poly-Ubiquitination and Degradation.

Tumor Suppressor SPOP Mediates the Proteasomal Degradation of Progesterone Receptors (prs) in Breast Cancer Cells

SPOP Promotes Tumor Progression Via Activation of Β-Catenin/tcf4 Complex in Clear Cell Renal Cell Carcinoma.

S119N Mutation of the E3 Ubiquitin Ligase SPOP Suppresses SLC7A1 Degradation to Regulate Hepatoblastoma Progression